| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2009 | CA2233166C Hormone immunomodulated induction of mucosal immune responses |
| 02/17/2009 | CA2217054C Compositions and methods for inhibiting thrombogenesis |
| 02/17/2009 | CA2157143C Alkylbenzoylguanidine derivatives |
| 02/15/2009 | CA2638448A1 Methods for preventing and treating tissue injury and sepsis associated with yersinia pestis infection |
| 02/13/2009 | CA2597193A1 Compounds and uses |
| 02/12/2009 | WO2009021235A2 Methods and compositions for treating cancer |
| 02/12/2009 | WO2009021169A2 (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation |
| 02/12/2009 | WO2009021155A1 Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| 02/12/2009 | WO2009021129A1 Sulfamide derivative useful for the treatment of epilepsy |
| 02/12/2009 | WO2009021121A2 Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto |
| 02/12/2009 | WO2009021113A1 Methods for enhancing glutahione peroxidase activity |
| 02/12/2009 | WO2009021106A1 Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms |
| 02/12/2009 | WO2009021083A1 Quinoxaline derivatives as pi3 kinase inhibitors |
| 02/12/2009 | WO2009021082A2 Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
| 02/12/2009 | WO2009021081A2 Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
| 02/12/2009 | WO2009021058A2 Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| 02/12/2009 | WO2009021055A1 Methods for treating dependence |
| 02/12/2009 | WO2009020990A1 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
| 02/12/2009 | WO2009020987A2 Process for preparation of swellable and degradable microspheres |
| 02/12/2009 | WO2009020960A1 Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase |
| 02/12/2009 | WO2009020897A1 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
| 02/12/2009 | WO2009020894A2 RNAι-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA |
| 02/12/2009 | WO2009020877A2 Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof |
| 02/12/2009 | WO2009020848A2 RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA |
| 02/12/2009 | WO2009020847A2 Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis |
| 02/12/2009 | WO2009020828A1 Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| 02/12/2009 | WO2009020814A2 Fused heterocycles |
| 02/12/2009 | WO2009020642A1 Pyridine carboxamide orexin receptor antagonists |
| 02/12/2009 | WO2009020641A1 Hybrid scfa-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders |
| 02/12/2009 | WO2009020631A2 Compounds for treating proliferative disorders |
| 02/12/2009 | WO2009020620A1 Synergisms between repartitioning and immunomodulating compounds |
| 02/12/2009 | WO2009020616A1 Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections |
| 02/12/2009 | WO2009020613A1 Modulation of cell junctions |
| 02/12/2009 | WO2009020590A1 Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| 02/12/2009 | WO2009020582A1 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | WO2009020579A1 Gamma secretase modulators |
| 02/12/2009 | WO2009020578A1 Alpha2c adrenoreceptor agonists |
| 02/12/2009 | WO2009020569A1 Treatment of psychosis with a 5ht2a antagonist and a metabotropic glutamate receptor agonist or potentiator |
| 02/12/2009 | WO2009020534A2 Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
| 02/12/2009 | WO2009020521A2 Identification and treatment of estrogen responsive prostate tumors |
| 02/12/2009 | WO2009020483A1 Crystalline forms of ibandronate sodium |
| 02/12/2009 | WO2009020480A2 Genomic mutation inhibitors that inhibit y family dna polymerases |
| 02/12/2009 | WO2009020457A2 Chemical compounds |
| 02/12/2009 | WO2009020448A1 Proteasome inhibitors |
| 02/12/2009 | WO2009020405A1 Treating or preventing rotavirus infection |
| 02/12/2009 | WO2009020270A1 Delivery system for nucleic acids using cationic polymer conjugates |
| 02/12/2009 | WO2009020234A2 Pyrrolidin-2 -one derivatives as androgen receptor modulator |
| 02/12/2009 | WO2009020231A1 Triterpene oxidase derived from plant belonging to genus glychyrrhiza, gene encoding the triterpene oxidase, and use of the protein or the gene |
| 02/12/2009 | WO2009020198A1 Aniline derivative having anti-dna virus activity |
| 02/12/2009 | WO2009020192A1 Composition for oral intake for preventing ultraviolet damage |
| 02/12/2009 | WO2009020145A1 Two-component eye drops containing pirenoxine |
| 02/12/2009 | WO2009020140A1 Adamantylurea derivative |
| 02/12/2009 | WO2009020137A1 Aminopyrazole amide derivative |
| 02/12/2009 | WO2009020119A1 Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| 02/12/2009 | WO2009020104A1 Gel-like composition for external application comprising adenine compound |
| 02/12/2009 | WO2009020028A1 Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell |
| 02/12/2009 | WO2009019868A1 10a-azalide compound crosslinked at position-10a and position-12 |
| 02/12/2009 | WO2009019708A2 Pharmaceutical compositions and methods for the treatment of cancer |
| 02/12/2009 | WO2009019693A2 Analgesic effect of jasmonate derivatives |
| 02/12/2009 | WO2009019662A2 Oral metaxalone compositions |
| 02/12/2009 | WO2009019656A1 Pyridyl derivatives, their preparation and use |
| 02/12/2009 | WO2009019607A2 Beta adrenergic receptor ligand derivatives for modulating apoptosis |
| 02/12/2009 | WO2009019599A2 Extended release compositions comprising tolterodine |
| 02/12/2009 | WO2009019598A2 Inhalation therapy for respiratory disorders |
| 02/12/2009 | WO2009019566A1 Phenoxy-pyrrolidine derivative and its use and compositions |
| 02/12/2009 | WO2009019555A2 Ophthalmic formulation containing paracetamol |
| 02/12/2009 | WO2009019553A2 Imidazopyridinones |
| 02/12/2009 | WO2009019518A1 Pyrimidine compounds having a fgfr inhibitory effect |
| 02/12/2009 | WO2009019508A1 Calcium ion channel modulators & uses thereof |
| 02/12/2009 | WO2009019506A1 Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| 02/12/2009 | WO2009019505A2 Drug combinations for the treatment of duchenne muscular dystrophy |
| 02/12/2009 | WO2009019503A2 P2x7 antagonists for use in the treatment of mood disorders |
| 02/12/2009 | WO2009019478A1 Treatments and prevention of hydrocephalus |
| 02/12/2009 | WO2009019473A1 Treatments for inflammatory arthritis |
| 02/12/2009 | WO2009019472A1 1, 2, 4 -triazole derivatives as serotonergic modulators |
| 02/12/2009 | WO2009019463A1 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue |
| 02/12/2009 | WO2009019446A1 Compounds useful as medicaments |
| 02/12/2009 | WO2009019445A1 Dithiazolidine and thiazolidine derivatives as anticancer agents |
| 02/12/2009 | WO2009019385A1 Use of eflucimibe for the production of a medicament for the prevention or treatment of a disease caused by sebaceous gland dysfunction in humans or animals |
| 02/12/2009 | WO2009019371A2 Use of a material based on a thermoplastic polymer having a high content of antioxidants for packaging dianhydrohexitols |
| 02/12/2009 | WO2009019307A2 Oral calcitonin compositions and applications thereof |
| 02/12/2009 | WO2009019303A2 A process for the preparation or purification of olmesartan medoxomil |
| 02/12/2009 | WO2009019294A2 Bupropion hydrobromide and therapeutic applications |
| 02/12/2009 | WO2009019286A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 02/12/2009 | WO2009019281A1 Benzoisoindole derivatives and their use as ep4 receptor agonists for the treatment of pain |
| 02/12/2009 | WO2009019278A1 Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| 02/12/2009 | WO2009019274A1 Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53 |
| 02/12/2009 | WO2009019211A1 Process for the preparation of methyl ester of rosuvastatin |
| 02/12/2009 | WO2009019205A1 Crystalline form of a dihydropteridione derivative |
| 02/12/2009 | WO2009019202A1 N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases |
| 02/12/2009 | WO2009019199A1 Crystalline teglicar |
| 02/12/2009 | WO2009019167A1 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis |
| 02/12/2009 | WO2009019149A1 Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
| 02/12/2009 | WO2009019133A1 Trazodone and trazodone hydrochloride in purified form |
| 02/12/2009 | WO2009019027A1 Use of 25-hydroxy vitamin d3 to increase muscle mass in mammals |
| 02/12/2009 | WO2009019014A1 Novel benzimidazol-2-yl-alkylamines and the use thereof as microbicidal agents |
| 02/12/2009 | WO2009019007A2 Sdf-1 binding nucleic acids and the use thereof |
| 02/12/2009 | WO2009018959A1 Salts of tramadol and naproxen and their crystal forms in the treatment of pain |
| 02/12/2009 | WO2009018909A2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 02/12/2009 | WO2009018834A1 Pharmaceutical composition containing bisphosphonate and method for the preparation thereof |